These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 18813135)

  • 81. The fragile X syndrome.
    de Vries BB; Halley DJ; Oostra BA; Niermeijer MF
    J Med Genet; 1998 Jul; 35(7):579-89. PubMed ID: 9678703
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Fragile X screening by quantification of FMRP in dried blood spots by a Luminex immunoassay.
    LaFauci G; Adayev T; Kascsak R; Kascsak R; Nolin S; Mehta P; Brown WT; Dobkin C
    J Mol Diagn; 2013 Jul; 15(4):508-17. PubMed ID: 23660422
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Rett-like syndrome in fragile X syndrome.
    Alembik Y; Dott B; Stoll C
    Genet Couns; 1995; 6(3):207-10. PubMed ID: 8588847
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Fragile X syndrome in South Carolina.
    Saul RA; Stevenson RE; Simensen RJ; Wilkes G; Alexander W; Taylor H
    J S C Med Assoc; 1982 Sep; 78(9):475-7. PubMed ID: 6958922
    [No Abstract]   [Full Text] [Related]  

  • 85. Klinefelter syndrome and associated fragile-X syndrome.
    Pueschel SM; O'Brien MM; Padre-Mendoza T
    J Ment Defic Res; 1987 Mar; 31 ( Pt 1)():73-9. PubMed ID: 3585988
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Cost-effectiveness analysis of prenatal population-based fragile X carrier screening.
    Musci TJ; Caughey AB
    Am J Obstet Gynecol; 2005 Jun; 192(6):1905-12; discussion 1912-5. PubMed ID: 15970847
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Mosaicism for FMR1 gene full mutation and intermediate allele in a female foetus: a postzygotic retraction event.
    Ferreira SI; Pires LM; Ferrão J; Sá J; Serra A; Carreira IM
    Gene; 2013 Sep; 527(1):421-5. PubMed ID: 23792063
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Clinical screening score for the fragile X (Martin-Bell) syndrome.
    Laing S; Partington M; Robinson H; Turner G
    Am J Med Genet; 1991; 38(2-3):256-9. PubMed ID: 2018069
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Molecular diagnosis of fragile X syndrome using methylation sensitive techniques in a cohort of patients with intellectual disability.
    Chaudhary AG; Hussein IR; Abuzenadah A; Gari M; Bassiouni R; Sogaty S; Lary S; Al-Quaiti M; Al Balwi M; Al Qahtani M
    Pediatr Neurol; 2014 Apr; 50(4):368-76. PubMed ID: 24630283
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Efficacy of cascade testing for fragile X syndrome.
    Wildhagen MF; van Os TA; Polder JJ; ten Kate LP; Habbema JD
    J Med Screen; 1999; 6(2):70-6. PubMed ID: 10444723
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Fragile X syndrome screening in pregnant women and women planning pregnancy shows a remarkably high FMR1 premutation prevalence in the Balearic Islands.
    Alfaro Arenas R; Rosell Andreo J; Heine Suñer D;
    Am J Med Genet B Neuropsychiatr Genet; 2016 Dec; 171(8):1023-1031. PubMed ID: 27333191
    [TBL] [Abstract][Full Text] [Related]  

  • 92. A 15-year-long Southern blotting analysis of FMR1 to detect female carriers and for prenatal diagnosis of fragile X syndrome in Taiwan.
    Tzeng CC; Tsai LP; Chang YK; Hung YJ; Chang YY; Su YP; Jiang JJ; Liang HM
    Clin Genet; 2017 Aug; 92(2):217-220. PubMed ID: 28139839
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The fragile X syndrome.
    Brown WT
    Neurol Clin; 1989 Feb; 7(1):107-21. PubMed ID: 2646518
    [TBL] [Abstract][Full Text] [Related]  

  • 94. ACOG committee opinion. No. 338: Screening for fragile X syndrome.
    American College of Obstetricians and Gynecologists Committee on Genetics
    Obstet Gynecol; 2006 Jun; 107(6):1483-5. PubMed ID: 16738187
    [TBL] [Abstract][Full Text] [Related]  

  • 95. [Fragile X syndrome: clinical and molecular genetics correlations].
    Froster UG
    Ther Umsch; 1995 Dec; 52(12):805-9. PubMed ID: 8539651
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Policy considerations in designing a fragile X population screening program.
    Ross LF; Acharya K
    Genet Med; 2008 Oct; 10(10):711-3. PubMed ID: 18813132
    [No Abstract]   [Full Text] [Related]  

  • 97. Should we implement population screening for fragile X?
    Dimmock DP
    Genet Med; 2017 Dec; 19(12):1295-1299. PubMed ID: 28771250
    [No Abstract]   [Full Text] [Related]  

  • 98. Attitudes toward population screening among people living with fragile X syndrome in the UK: 'I wouldn't wish him away, I'd just wish his fragile X syndrome away'.
    Boardman FK
    J Genet Couns; 2021 Feb; 30(1):85-97. PubMed ID: 33184995
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Validation of Fragile X Screening in the Newborn Population Using a Fit-for-Purpose FMR1 PCR Assay System.
    Lee S; Taylor JL; Redmond C; Hadd AG; Kemppainen JA; Haynes BC; Shone S; Bailey DB; Latham GJ
    J Mol Diagn; 2020 Mar; 22(3):346-354. PubMed ID: 31866572
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Molecular Correlates and Recent Advancements in the Diagnosis and Screening of FMR1-Related Disorders.
    Rajan-Babu IS; Chong SS
    Genes (Basel); 2016 Oct; 7(10):. PubMed ID: 27754417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.